Many people may not receive a COVID-19 vaccine until 2022
Studies show that more than a fifth of the global population, mostly in low- and middle-income countries, may have to wait until at least 2022 to receive a COVID-19 vaccine.
List view / Grid view
Studies show that more than a fifth of the global population, mostly in low- and middle-income countries, may have to wait until at least 2022 to receive a COVID-19 vaccine.
Within this in-depth focus are articles explaining the numerous benefits of in vitro human cell-based kidney models to study nephrotoxicity and drug-to-drug interactions as well as discussing the measures taken by API manufacturers to successfully navigate the pandemic and the opportunities this presents.
This issue focuses on whether our vaccine innovation capabilities will prepare us for future outbreaks, how Raman spectroscopy can be used to rapidly detect SARS-CoV-2 and the development of high-throughput glycoanalytics for biopharmaceuticals. Also included are articles on opportunities in the global API market and how to successfully identify defects…
A combined testing procedure to overcome the manufacturing bottleneck caused by the time needed for compendial bioburden testing according to EP.
Upholding biosafety standards in coronavirus vaccine development and manufacturing despite the acute worldwide need.
Here are five ways to ensure a successful and compliant cleaning validation program.
Practical Tips for Monomer/Aggregate and Fragment Content Monitoring of monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs).
Single-use systems come with their own extractables and leachables challenges. Although there are no formal guidelines yet, safety must be assessed.
Secure your Pharma analysis & QC - Take your journey through our small molecules and biologics analysis & QC regulatory compliant portfolio.
The WHO Regional Director for Africa urges governments to “ramp up readiness” as report suggests the region is not prepared for a COVID-19 vaccine roll-out.
The strategy outlines actions to strengthen EU supply chains, encourage innovation and ensure medicines are affordable and sustainable.
A single-use, self-administered microneedle vaccine has been developed to provide immunisation against infectious diseases.
A new nasal spray with ingredients already approved for use in humans could be used to protect people against COVID-19.
Report reveals global pharma supply chain leaders are afraid of the vulnerabilities in the end-to-end supply chain as the COVID-19 pandemic continues.
At Lonza, we have developed our CFS 1200® capsule filling and sealing machine as part of our Lonza Engine™ portfolio. Used with our Capsugel® capsules, pharmacies can automate this process to optimise operations and accuracy. This fact sheet will introduce you to its handling and sealing capabilities, key benefits, performance…